Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the development, manufacture, market and distribution of generic pharmaceutical products. It operates through the Generic, Specialty and AvKARE Segments. The Generics segment develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products and transdermals. The Specialty segment provides proprietary medicines to the U.S. market. The AvKARE segment focuses on pharmaceuticals, medical and surgical products, and services primarily to governmental agencies. The company was founded by Chintu Patel and Chirag Patel in 2002 and is headquartered in Bridgewater, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Amneal Pharmaceuticals reports strong Q4 earnings and outlines growth strategies

Amneal Pharmaceuticals delivered strong Q4 2022 results with revenue of $610 million and adjusted EBITDA of $154 million, expecting stable performance in 2023 with total revenue of $2.25-2.35 billion.
The company's strategic focus on complex, high-growth products, international expansion, and new product launches positions it for growth opportunities despite challenges in generic growth rates and competitive pressures.
With a robust biosimilars growth plan, unique pricing strategies, and market expansion initiatives, Amneal Pharmaceuticals aims to capture market share, drive revenue growth, and sustain its performance in the pharmaceutical industry.
Despite facing challenges such as potential competition and manufacturing delays, Amneal Pharmaceuticals remains optimistic about its growth prospects, emphasizing long-term strategies for revenue expansion and market positioning.

Amneal Pharmaceuticals reports strong Q1 results and eyes strategic growth

Amneal Pharmaceuticals' Q1 2023 performance reflects strategic growth initiatives across all segments, positioning the company for future success.
While challenges like debt reduction and refinancing exist, the company's strengths in product diversification and market adoption offer growth potential.
Opportunities in Injectables, Biosimilars, and capital allocation strategies provide avenues for revenue growth and operational excellence.

Amneal Pharmaceuticals reports strong Q2 earnings, eyes sustainable growth

Amneal Pharmaceuticals is on track for sustainable growth and EBITDA acceleration.
The company is well-positioned to capitalize on the growth potential in biosimilars and complex generics.
With a focus on organic growth and new product launches, Amneal aims to drive revenue and expand market share.

Amneal Pharmaceuticals excels in Q3, eyes international expansion and specialty growth

Amneal Pharmaceuticals reported strong financials, raised guidance, and highlighted growth in key segments. The company's strategic focus on operational efficiency, supply chain expansion, and international growth positions it for sustained success. Challenges include managing expenses and liabilities, but opportunities in new markets and product segments offer avenues for growth.

Amneal Pharmaceuticals posts record revenue in Q4 2023, eyes biosimilar growth

Amneal Pharmaceuticals reported robust financials for Q4 2023 and full-year 2023, with record revenue and EBITDA figures. The company's strategic focus on biosimilars, portfolio expansion, and growth initiatives underpin its optimistic outlook for 2024. Despite industry challenges, Amneal remains committed to innovation, affordability, and addressing pricing issues.

Amneal Pharmaceuticals reports record Q1 revenues and eyes biosimilar growth

Amneal Pharmaceuticals' Q1 performance reflects robust growth across all segments, underpinned by strong financial execution and a sustainable growth profile.
The company's strengths lie in its market position, diverse portfolio, commitment to quality, and strategic partnerships, positioning them for continued success.
While facing challenges related to product approvals and revenue uncertainties, Amneal is well-positioned to capitalize on opportunities in biosimilars, strategic partnerships, and market expansion.

Amneal Pharmaceuticals excels in Q2, eyes international expansion for growth

Amneal Pharmaceuticals delivered a strong performance in Q2 2024, with robust revenue growth and raised guidance, signaling confidence in future prospects.
The company's strategic strengths lie in international expansion, diversified revenue streams, and a focus on financial stability through debt reduction and investments.
Challenges include maintaining growth momentum, effective execution of expansion plans, and balancing debt reduction with growth investments.
Opportunities abound in new product approvals, market expansion, and innovation, positioning Amneal Pharmaceuticals for sustained growth and market leadership.

Amneal Pharmaceuticals reports robust Q3 results and eyes future growth

Amneal Pharmaceuticals' Q3 performance reflects strong revenue growth and strategic product initiatives in key therapeutic areas.
The company's focus on affordable medicines, biosimilars, and strategic investments underscores its commitment to future growth.
While facing challenges in market competition and operational optimization, Amneal is well-positioned to leverage growth opportunities.
With a solid financial performance and a focus on sustainable value creation, Amneal is poised for long-term success in the pharmaceutical industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amneal Pharmaceuticals, Inc. is a medicine company, which engages in the provision of pharmaceuticals. Its product portfolio includes generics, specialty, biosciences, and product catalog. It operates through the following segments: Generics, Specialty, and AvKARE. The Generics segment relates to oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmics, films, and transdermal patches and topicals. The Specialty segment refers to the development, promotion, sale, and distribution of proprietary branded pharmaceutical products. The AvKARE segment provides pharmaceuticals, medical, and surgical products and services to governmental agencies. The company was founded by Chirag K. Patel and Chintu Patel in 2002 and is headquartered in Bridgewater, NJ.

ORION CORPORATION PRESS RELEASE 4 JANUARY 2023 at 16.00 EET

Orion and Amneal enter strategic partnership – Orion receives exclusive licence to commercialise Amneal's generic products in Europe, Australia and New Zealand

BRIDGEWATER, N.J.--( BUSINESS WIRE )--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced it has signed a long-term license agreement with Orion Corporation (OMXH: ORNBV & ORNAV) to commercialize a number of Amneal's complex generic products.

Amneal Announces Strategic European Partnership with Orion Corporation

BRIDGEWATER, N.J.--( BUSINESS WIRE )--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that the Company has successfully launched 26 new generic products in 2022. In the fourth quarter of 2022, the Company launched 8 new generic products, including clindamycin phosphate gel 1%, ipratropium bromide nasal sprays, and prednisolone sodium phosphate oral solution.

Amneal Announces 26 Generic New Product Launches in 2022 and First Injection Large Volume Bag Approval

BRIDGEWATER, N.J.--( BUSINESS WIRE )--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced the commercial launch of RELEUKO® (filgrastim-ayow), a biosimilar referencing Neupogen®. RELEUKO® is used to treat neutropenia which is commonly experienced by patients undergoing chemotherapy. This product was developed in collaboration with Kashiv Biosciences, LLC located in Chicago, Illinois.

Amneal Launches Second Biosimilar with RELEUKO® (filgrastim-ayow) in the United States

Amneal Pharmaceuticals' (AMRX) shares rise after the company announces that its Parkinson's candidate IPX203 NDA has been accepted for review by the FDA.

FDA Accepts Amneal's (AMRX) Parkinson's Candidate NDA For Review

BRIDGEWATER, N.J.--( BUSINESS WIRE )--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for IPX203 for the treatment of Parkinson's disease (PD). IPX203 is a novel, oral formulation of carbidopa/levodopa (CD/LD) extended-release capsules.

Amneal Announces U.S. FDA Filing Acceptance of New Drug Application for IPX203 for the Treatment of Parkinson's Disease

Amneal Pharmaceuticals, Inc. (NYSE:AMRX ) Q3 2022 Earnings Conference Call November 4, 2022 8:30 AM ET Company Participants Chirag Patel - Co-Founder, Co-Chief Executive Officer Chintu Patel - Co-Founder and Co-Chief Executive Officer Anastasios Konidaris - Executive Vice President and Chief Financial Officer Harsher Singh - Senior Vice President, Biosciences Jason Daly - Senior Vice President and Chief Legal Officer Gustavo Pesquin - EVP, Specialty Conference Call Participants David Amsellem - Piper Sandler Michaela Diverio - Barclays Gary Nachman - BMO Capital Markets Nathan Rich - Goldman Sachs Elliot Wilbur - Raymond James Gregory Fraser - Truist Securities Operator Hello everyone and welcome to the Amneal Third Quarter 2022 Conference Call. My name is Emily and I will be your operator today.

Amneal Pharmaceuticals, Inc. (AMRX) Q3 2022 Earnings Call Transcript

Amneal (AMRX) delivered earnings and revenue surprises of -22.22% and 3.37%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Amneal Pharmaceuticals (AMRX) Q3 Earnings and Revenues Lag Estimates

Amneal Reports Third Quarter 2022 Financial Results

Amneal Receives FDA Approval for Leuprolide Acetate Injection

Amneal Expands Leadership Team with Appointment of Senior Leaders in Quality and Regulatory

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its third quarter 2022 financial results on Friday November 4, 2022, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time on November 4, 2022. The financial results and live webcast will be accessible through the Investor Relations section of the Company's website at https://investors.amneal.

Amneal to Report Third Quarter 2022 Results on November 4, 2022

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced the commercial launch of ALYMSYS® (bevacizumab-maly), a biosimilar referencing Avastin®. ALYMSYS® is a vascular endothelial growth factor inhibitor used in oncology. This product was developed by mAbxience, a global biotech company with over a decade of experience in the development, manufacture, and commercialization of biopharmaceuticals. “The launch of ALYMSYS provides ad

Amneal Launches First Biosimilar with ALYMSYS® (bevacizumab-maly) in the United States

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced it has appointed Gustavo Pesquin as Executive Vice President, Chief Commercial Officer - Specialty, effective September 6, 2022. Mr. Pesquin joins the Company from Sanofi, a global pharmaceutical company, where he served leadership roles of increasing responsibility over his 11-year tenure, including most recently as North America Head for General Medicines. Prior to that, M

Amneal Appoints Gustavo Pesquin as Executive Vice President, Chief Commercial Officer – Specialty

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for IPX203, a novel, oral formulation of carbidopa/levodopa (CD/LD) extended-release capsules for the treatment of Parkinson's disease (PD). The submission is based on results from the pivotal Phase 3 RISE-PD clinical trial demonstrating more “Good On” time compared to immediate-release CD/LD, even when IPX203

Amneal Announces Submission of New Drug Application to the U.S. FDA for IPX203 for the Treatment of Parkinson's Disease

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced its support of the creation of the bipartisan Congressional Domestic Pharmaceutical Manufacturing Caucus. This caucus will focus on securing America's pharmaceutical supply chain by ensuring that essential medicines are manufactured in the U.S. This working group will led by Rep. Gus Bilirakis (R-FL), Rep. Earl L. "Buddy" Carter (R-GA), Rep. Chrissy Houlahan (D-PA), and Rep.

Amneal supports Congress' efforts to ensure essential medicines are Made in America

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (“FDA”) for four generics products, including vasopressin injection 1mL (single-dose). The four recently approved products include:   Product Dosage Category U.S. TTM IQVIA sales (June 2022) 1 Vasopressin injection 1mL Injectable $624 million 2 Famotidine for oral

Amneal launches 4 new Generic products, including Vasopressin single-dose

Amneal Pharmaceuticals, Inc. (NYSE:AMRX ) Q2 2022 Earnings Conference Call August 5, 2022 8:30 AM ET Company Participants Anthony DiMeo - Senior Director of Investor Relations Chirag Patel - Co-Founder, Co-Chief Executive Officer, President & Director Chintu Patel - Co-Founder & Co-Chief Executive Officer Anastasios Konidaris - Executive Vice President & Chief Financial Officer Harsher Singh - Head of Biosciences Jason Daly - Senior Vice President, Chief Legal Officer & Corporate Secretary Conference Call Participants Balaji Prasad - Barclays Nathan Rich - Goldman Sachs David Amsellem - Piper Sandler Gary Nachman - BMO Capital Markets Greg Fraser - Truist Securities Elliot Wilbur - Raymond James Ekaterina Knyazkova - JPMorgan Operator Hello and welcome to today's Amneal 2Q 2022 Earnings Conference Call. My name is Elliot and I will be coordinating your call today.

Amneal Pharmaceuticals, Inc. (AMRX) Management Team on Q2 2022 Results - Earnings Call Transcript

Amneal (AMRX) delivered earnings and revenue surprises of -5% and 4.63%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Amneal Pharmaceuticals (AMRX) Lags Q2 Earnings Estimates

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) announced its results today for the second quarter ended June 30, 2022. “Solid second quarter results reflect topline growth across all three segments and meaningful acceleration in performance from the first quarter. Our core business is strong as we expect acceleration in the second half of 2022 and further momentum in the years ahead. On the horizon are a number of key catalyst launches

Amneal Reports Second Quarter 2022 Financial Results

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that Deborah M. Autor has been appointed to the Company's Board of Directors, effective July 29, 2022. Chirag and Chintu Patel, Co-Chief Executive Officers, stated, “Deb brings decades of global public and private expertise in the biopharmaceutical sector to our board at an important time of growth for Amneal. She has a proven track record of service and impact throughout he

Amneal Appoints Deborah M. Autor to Board of Directors

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its second quarter 2022 financial results on Friday August 5, 2022, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time on August 5, 2022. The financial results and live webcast will be accessible through the Investor Relations section of the Company's website at https://investors.amneal.com

Amneal to Report Second Quarter 2022 Results on August 5, 2022

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced the release of its second annual (2021) Corporate Responsibility Report. The report showcases the Company's continued progress in deepening its commitment to environmental, social, and governance (ESG) integration across Amneal strategy, culture and operations. Updates on actions the Company has taken in key ESG areas are highlighted alongside the social impacts of our busin

Amneal Releases 2021 Corporate Responsibility Report Highlighting Continued ESG Impact and Integration

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced the commercial launch of LYVISPAH®, a baclofen oral granules (5, 10 and 20 mg) specialty product approved by the U.S. Food and Drug Administration (“FDA”) for the treatment of spasticity related to multiple sclerosis and other spinal cord disorders. LYVISPAH is bioequivalent to oral baclofen tablets and provides flexible, customized dosing with 5mg, 10mg and 20mg single-dose

Amneal Launches LYVISPAH® (baclofen) for Spasticity Related to Multiple Sclerosis and Other Spinal Cord Disorders

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that the U.S. Food and Drug Administration (“FDA”) has approved the Company's Biologics License Application (“BLA”) for pegfilgrastim-pbbk, a biosimilar referencing Neulasta®. The product will be marketed under the proprietary name FYLNETRA™. FYLNETRA was developed in collaboration with Kashiv Biosciences, LLC, located in Chicago, Illinois. It is used to treat neutropenia (l

News for Amneal Pharmaceuticals Stock (AMRX)